By Michael Dabaie

Clinical-stage immuno-oncology company Forty Seven Inc. (FTSV) said it will collaborate with AstraZeneca PLC's (AZN) Acerta Pharma.

Acerta will sponsor a clinical trial evaluating Forty Seven's CD47 antibody 5F9 in combination with rituximab plus Acerta's Calquence in patients with diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin's lymphoma.

The study aims to build on results already reported from a Phase 1b study of 5F9 in combination with rituximab in non-Hodgkin's lymphoma patients by including a third agent, acalabrutinib, the company said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

May 10, 2019 08:40 ET (12:40 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Astrazeneca Charts.